Foghorn Therapeutics

About:

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Website: http://foghorntx.com/

Twitter/X: foghorntx

Top Investors: Invus, Flagship Pioneering, Casdin Capital, Irving Investors

Description:

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

Total Funding Amount:

$221M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)foghorntx.com

Founders:

Cigall Kadoch

Number of Employees:

101-250

Last Funding Date:

2024-05-20

IPO Status:

Public

Industries:

© 2025 bioDAO.ai